Tandem Diabetes Care Announces Fourth Quarter and Full Year 2020 Financial Results and 2021 Financial Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500, Dow rise on Mideast deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Tandem Diabetes (TNDM) Tops Q4 EPS by 10c, Revenues Beat; Offers FY21 Revenues Guidance Above Consensus
February 24, 2021 4:35 PM ESTTandem Diabetes (NASDAQ: TNDM) reported Q4 EPS of $0.22, $0.10 better than the analyst estimate of $0.12. Revenue for the quarter came in at $168.1 million versus the consensus estimate of $141.58 million.
Fourth Quarter and Full Year 2020 Highlights
In comparing the fourth quarter of 2020 to the same period of 2019:
Worldwide pump shipments increased 67 percent to 32,685 pumpsSales increased 55 percent to $168.1 millionAdjusted... More